Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

TransMedics Group Inc logo
TMDX

TransMedics Group Inc

MaveScore 24 Low model confidence
Last Price US$75.48 As of Jun 15, 2026
Market Cap US$2.6b Company size context
7D Performance 6.10% Past 7 days
1Y Performance -39.25% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Mar 31, 2026

77 days old

Market price date

Jun 15, 2026

1 day old

Coverage

16/16

No missing model inputs

Data quality

Excellent

Current stored snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 24 Low confidence

Stored data quality

Freshness and coverage checks

Latest stored fundamentals and price inputs are recent enough for normal research review.

16/16 Current stored snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

17/35 Mixed

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

6/25 Weak

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

1/15 Weak

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

0/15 Weak

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

0/10 Weak

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Financial strength rewards durable profitability, margins, and positive free cash flow.
  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.
  • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Dashboard Funda..tals Deep..lue Prediction Screener Map

TransMedics Group Inc Overview

Industry: Medical Devices

Sector: Healthcare

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review TransMedics Group Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



TransMedics Group Inc Competitors

TransMedics Group Inc operates in the Medical Devices industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

TransMedics Group Inc

US$75.48

US$2.6b

6.10%

-39.25%